Popular Trials
Radioisotope Therapy
Rhenium Re 188 P2045 for Lung Cancer
This trial tests a new drug called Rhenium Re 188 P2045 on lung cancer patients. It aims to find a safe dose and check if it helps reduce tumors. Patients are monitored closely for side effects and tumor response.
MDM2 Inhibitor
Brigimadlin for Solid Cancers
This trial is testing a medicine called BI 907828 for adults with advanced cancer in the biliary tract, pancreas, lung, or bladder who have no other treatment options. The medicine is taken as a tablet periodically and works by blocking a protein that helps cancer cells grow.
Behavioural Intervention
Decision Coaching for Lung Cancer Screening
This trial is testing whether navigator decision coaching, compared to enhanced usual care, results in better decision making for lung cancer screening, more screenings, and increased adherence to repeat screenings and diagnostic testing. A booster coaching session is also being tested to see if it increases adherence to repeat screenings.
Microwave Ablation
Microwave Ablation for Lung Cancer
This trial tests a new procedure that uses microwave energy to destroy lung tumors. It targets patients with a few metastatic lung tumors. The treatment involves a device that heats and kills cancer cells, guided by robotic and imaging technology for accuracy. This developing treatment option offers advantages such as larger treatment areas and shorter heating times compared to other methods.
Popular Filters
Trials for NSCLC Patients
EGFR Inhibitor
Osimertinib + BLU-945 for Non-Small Cell Lung Cancer
This trial is testing BLU-945, a new drug that targets cancer proteins, alone or with osimertinib. It focuses on patients with specific EGFR gene mutations. The drug aims to block a protein that helps cancer cells grow.
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Checkpoint Inhibitor
Pembrolizumab + Chemoradiation +/- Olaparib for Stage III Lung Cancer
This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Trials for Non-Small Cell Lung Cancer Patients
EGFR Inhibitor
Osimertinib + BLU-945 for Non-Small Cell Lung Cancer
This trial is testing BLU-945, a new drug that targets cancer proteins, alone or with osimertinib. It focuses on patients with specific EGFR gene mutations. The drug aims to block a protein that helps cancer cells grow.
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Checkpoint Inhibitor
Pembrolizumab + Chemoradiation +/- Olaparib for Stage III Lung Cancer
This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Trials for EGFR Positive Patients
EGFR Inhibitor
Osimertinib + BLU-945 for Non-Small Cell Lung Cancer
This trial is testing BLU-945, a new drug that targets cancer proteins, alone or with osimertinib. It focuses on patients with specific EGFR gene mutations. The drug aims to block a protein that helps cancer cells grow.
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Trials for ALK Positive Patients
Tyrosine Kinase Inhibitor
Alectinib vs Crizotinib for Non-Small Cell Lung Cancer
This trial compares two medications, alectinib and crizotinib, for treating a specific type of advanced lung cancer. The patients have not received any prior treatment for their cancer. Both drugs work by blocking a protein that helps the cancer cells grow. Alectinib has shown superior effectiveness and fewer side effects compared to crizotinib in treating this type of lung cancer.
Tyrosine Kinase Inhibitor
Crizotinib for Non-Small Cell Lung Cancer
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Phase 3 Trials
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Checkpoint Inhibitor
Pembrolizumab + Chemoradiation +/- Olaparib for Stage III Lung Cancer
This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.
Topoisomerase I inhibitors
Etoposide for Small Cell Lung Cancer
This trial uses Etoposide to treat small cell lung cancer patients. It aims to understand how differences in two specific genes affect treatment success and safety. Researchers study these genes to find links between genetic differences and how patients respond to the drug.
Alkylating agents
Radiation + Chemotherapy for Small Cell Lung Cancer
This trial is testing different radiation therapy regimens to see which is more effective in treating patients with limited-stage small cell lung cancer when given together with chemotherapy.
Tyrosine Kinase Inhibitor
Alectinib vs Crizotinib for Non-Small Cell Lung Cancer
This trial compares two medications, alectinib and crizotinib, for treating a specific type of advanced lung cancer. The patients have not received any prior treatment for their cancer. Both drugs work by blocking a protein that helps the cancer cells grow. Alectinib has shown superior effectiveness and fewer side effects compared to crizotinib in treating this type of lung cancer.
Trials With No Placebo
EGFR Inhibitor
Osimertinib + BLU-945 for Non-Small Cell Lung Cancer
This trial is testing BLU-945, a new drug that targets cancer proteins, alone or with osimertinib. It focuses on patients with specific EGFR gene mutations. The drug aims to block a protein that helps cancer cells grow.
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
View More Related Trials
Frequently Asked Questions
Introduction to metastatic lung cancer
What are the top hospitals conducting metastatic lung cancer research?
In the battle against metastatic lung cancer, several hospitals are leading the charge in pioneering clinical trials. At the University of California Davis Comprehensive Cancer Center in Sacramento, researchers are currently conducting seven active trials focused on this aggressive form of cancer. Their commitment to finding innovative treatments is evident through their impressive 62 previous trials dedicated to metastatic lung cancer since embarking on their first study in 2006. Similarly, UC San Diego Moores Cancer Center in La Jolla is actively engaged in six ongoing trials for metastatic lung cancer and has a respectable track record with 45 completed studies dating back to their inaugural trial in 2009.
Meanwhile, at Sutter Roseville Medical Center located in Roseville, a dedicated team of experts is undertaking five active clinical trials targeting metastatic lung cancer. Over the years, they have accumulated valuable knowledge from their involvement in 31 past investigations since commencing research efforts into this condition back in 2004. Additionally contributing to advancements within this field are Sutter Cancer Centers Radiation Oncology Services-Auburn and Sutter Cancer Centers Radiation Oncology Services-Cameron Park; both facilities offer valuable opportunities for patients to participate in cutting-edge research as they each conduct five ongoing clinical trials related to metastatic lung cancer while having previously conducted eighteen such studies starting from the year2008
These hospitals represent beacons of hope for those affected by advanced-stage lung cancer by pushing boundaries and expanding our understanding of treatment options available. Through these collective endeavors across various locations within California's healthcare landscape lies an unwavering determination towards finding innovative approaches that could potentially transform outcomes for patients facing metastatic lung cancer.
Which are the best cities for metastatic lung cancer clinical trials?
When it comes to metastatic lung cancer clinical trials, several cities have emerged as prominent hubs of research and innovation. Sacramento, California leads the way with 29 active trials investigating treatments such as Crizotinib, High Radiation Dose Therapy, and Subprotocol C2 (MET exon 14 deletion/mutation). Anchorage, Alaska closely follows with 25 ongoing studies focusing on therapies like High Radiation Dose Therapy and Crizotinib. New york City also plays a significant role in this field with 23 active trials exploring treatments including Amivantamab and brigimadlin (BI 907828) treatment arm. Los Angeles and Boston are not far behind, each hosting 23 and 22 active trials respectively. These cities offer individuals affected by metastatic lung cancer access to cutting-edge clinical trials that pave the way for advancements in care and provide hope for better outcomes.
Which are the top treatments for metastatic lung cancer being explored in clinical trials?
Metastatic lung cancer research is advancing rapidly, with several promising treatments at the forefront of clinical trials. Pembrolizumab stands out as a leading contender, currently being explored in six active trials dedicated to metastatic lung cancer. Since its initial listing in 2011, it has amassed an impressive 190 all-time trials focused on combating this aggressive disease. Nivolumab closely follows with four ongoing trials and a robust history of 131 all-time metastatic lung cancer studies since its introduction in 2011. Another noteworthy treatment is atezolizumab, presently under investigation in two active trials and boasting an impressive track record of 81 all-time clinical trials since its debut in 2013. Last but not least, paclitaxel brings decades of experience to the table, participating in two current metastatic lung cancer studies alongside an extensive portfolio of 189 previous clinical investigations dating back to 2002. These innovative therapies offer renewed hope for patients battling metastatic lung cancer around the world.
What are the most recent clinical trials for metastatic lung cancer?
Recent clinical trials offer promising prospects for patients with metastatic lung cancer. Among them, the brigimadlin (BI 907828) treatment arm demonstrated encouraging results in Phase 2, highlighting its potential as a therapeutic option. Another trial focused on sitravatinib, aiming to determine its efficacy in treating this aggressive form of cancer. Additionally, BLU-945 underwent both Phase 1 and Phase 2 testing to evaluate its effectiveness against metastatic lung cancer. Further advancements include the investigation of pembrolizumab/vibostolimab in a Phase 3 trial and exploring the benefits of thoracic radiotherapy through another Phase 3 study. These recent breakthroughs bring renewed hope for improved outcomes and enhanced quality of life for individuals battling metastatic lung cancer.
What metastatic lung cancer clinical trials were recently completed?
A multitude of clinical trials investigating potential treatments for metastatic lung cancer have recently concluded, showcasing the ongoing efforts to combat this challenging disease. Noteworthy completed studies include Vergent Bioscience's trial on VGT-309 in May 2022, Erasca Inc.'s trial on ERAS-007 in September 2021, and Mirati Therapeutics Inc.'s trial on MRTX849 in August 2021. Other significant trials that wrapped up earlier include Ociperlimab by BeiGene and Probiotic by Mayo Clinic (both completed July 2021), Berzosertib by EMD Serono Research & Development Institute (completed March 2021), Osimertinib by M.D. Anderson Cancer Center (completed June 2020), and Proton beam therapy RT by Case Comprehensive Cancer Center (completed August 2019).